|
1
|
Zhao R, Davey M, Hsu YC, et al: Navigating
the chaperone network: an integrative map of physical and genetic
interactions mediated by the hsp90 chaperone. Cell. 120:715–727.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Trepel J, Mollapour M, Giaccone G and
Neckers L: Targeting the dynamic HSP90 complex in cancer. Nat Rev
Cancer. 10:537–549. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Taipale M, Jarosz DF and Lindquist S:
HSP90 at the hub of protein homeostasis: emerging mechanistic
insights. Nat Rev Mol Cell Biol. 11:515–528. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Whitesell L and Lindquist SL: HSP90 and
the chaperoning of cancer. Nature Rev Cancer. 5:761–772. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kamal A, Thao L, Sensintaffar J, Zhang L,
Boehm MF, Fritz LC and Burrows FJ: A high-affinity conformation of
Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature.
425:407–410. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim YS, Alarcon SV, Lee S, Lee MJ,
Giaccone G, Neckers L and Trepel JB: Update on Hsp90 inhibitors in
clinical trial. Curr Top Med Chem. 9:1479–1492. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ge J, Normant E, Porter JR, et al: Design,
synthesis, and biological evaluation of hydroquinone derivatives of
17-amino-17-demethoxygeldanamycin as potent, water-soluble
inhibitors of Hsp90. J Med Chem. 49:4606–4615. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Floris G, Debiec-Rychter M, Wozniak A,
Stefan C, Normant E, Faa G, Machiels K, Vanleeuw U, Sciot R and
Schöffski P: The heat shock Protein 90 inhibitor IPI-504 induces
KIT degradation, tumor shrinkage, and cell proliferation arrest in
xenograft models of gastrointestinal stromal tumors. Mol Cancer
Ther. 10:1897–1908. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gaspar N, Sharp SY, Eccles SA, Gowan S,
Popov S, Jones C, Pearson A, Vassal G and Workman P: Mechanistic
evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and
pediatric glioblastoma. Mol Cancer Ther. 9:1219–1233. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sausville EA, Tomaszewski JE and Ivy P:
Clinical development of 17-allylamino, 17-demethoxygeldanamycin.
Curr Cancer Drug Targets. 3:377–383. 2003. View Article : Google Scholar
|
|
11
|
Banerji U, O’Donnell A, Scurr M, et al:
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino,
17-demethoxygeldanamycin in patients with advanced malignancies. J
Clin Oncol. 23:4152–4161. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Modi S, Stopeck AT, Gordon MS, et al:
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is
safe and active in trastuzumab-refractory HER-2 overexpressing
breast cancer: a phase I dose-escalation study. J Clin Oncol.
25:5410–5417. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Modi S, Stopeck A, Linden H, et al: HSP90
inhibition is effective in breast cancer: a phase II trial of
tanespimycin (17-AAG) plus trastuzumab in patients with
HER2-positive metastatic breast cancer progressing on trastuzumab.
Clin Cancer Res. 17:5132–5139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vaishampayan UN, Burger AM, Sausville EA,
Heilbrun LK, Li J, Horiba MN, Egorin MJ, Ivy P, Pacey S and Lorusso
PM: Safety, efficacy, pharmacokinetics, and pharmacodynamics of the
combination of sorafenib and tanespimycin. Clin Cancer Res.
16:3795–3804. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar
|
|
17
|
Wu X, Wanders A, Wardega P, et al: Hsp90
is expressed and represents a therapeutic target in human
oesophageal cancer using the inhibitor
17-allylamino-17-demethoxygeldanamycin. Br J Cancer. 100:334–343.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eccles SA, Massey A, Raynaud FI, et al:
NVP-AUY922: a novel heat shock protein 90 inhibitor active against
xenograft tumor growth, angiogenesis, and metastasis. Cancer Res.
68:2850–2860. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ueno T, Tsukuda K, Toyooka S, et al:
Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on
non-small cell lung cancer. Lung Cancer. 76:26–31. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee KH, Lee JH, Han SW, Im SA, Kim TY, Oh
DY and Bang YJ: Antitumor activity of NVP-AUY922, a novel heat
shock protein 90 inhibitor, in human gastric cancer cells is
mediated through proteasomal degradation of client proteins. Cancer
Sci. 102:1388–1395. 2011. View Article : Google Scholar
|
|
21
|
Manning BD and Cantley LC: AKT/PKB
signaling: navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Johnson GL and Lapadat R:
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and
p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Salmena L, Carracedo A and Pandolfi PP:
Tenets of PTEN Tumor Suppression. Cell. 133:403–414. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stambolic V, Suzuki A, de la Pompa JL,
Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM,
Siderovski DP and Mak TW: Negative regulation of PKB/Akt-dependent
cell survival by the tumor suppressor PTEN. Cell. 95:29–39. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu X, Senechal K, Neshat MS, Whang YE and
Sawyers CL: The PTEN/MMAC1 tumor suppressor phosphatase functions
as a negative regulator of the phosphoinositide 3-kinase/Akt
pathway. Proc Natl Acad Sci USA. 95:15587–15591. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tachibana M, Shibakita M, Ohno S, Kinugasa
S, Yoshimura H, Ueda S, Fujii T, Rahman MA, Dhar DK and Nagasue N:
Expression and prognostic significance of PTEN product protein in
patients with esophageal squamous cell carcinoma. Cancer.
94:1955–1960. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Song CH, Park SY, Eom KY, Kim JH, Kim SW,
Kim JS and Kim IA: Potential prognostic value of heat-shock protein
90 in the presence of phosphatidylinositol-3-kinase overexpression
or loss of PTEN, in invasive breast cancers. Breast Cancer Res.
12:R202010. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Basso AD, Solit DB, Chiosis G, Giri B,
Tsichlis P and Rosen N: Akt forms an intracellular complex with
heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by
inhibitors of Hsp90 function. J Biol Chem. 277:39858–39866. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiao Y, Ou W, Meng F, Zhou H and Wang A:
Targeting HSP90 in ovarian cancers with multiple receptor tyrosine
kinase coactivation. Mol Cancer. 10:1252011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Scaltriti M, Serra V, Normant E, et al:
Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive
trastuzumab-resistant breast cancer. Mol Cancer Ther. 10:817–824.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yamamoto C, Basaki Y, Kawahara A, et al:
Loss of PTEN expression by blocking nuclear translocation of EGR1
in gefitinib-resistant lung cancer cells harboring epidermal growth
factor receptor-activating mutations. Cancer Res. 70:8715–8725.
2010. View Article : Google Scholar
|
|
32
|
Paraiso KH, Xiang Y, Rebecca VW, et al:
PTEN loss confers BRAF inhibitor resistance to melanoma cells
through the suppression of BIM expression. Cancer Res.
71:2750–2760. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu H, Woolfenden S, Bronson RT, Jaffer
ZM, Barluenga S, Winssinger N, Rubenstein AE, Chen R and Charest A:
The novel Hsp90 inhibitor NXD30001 induces tumor regression in a
genetically engineered mouse model of glioblastoma multiforme. Mol
Cancer Ther. 9:2618–2626. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Darido C, Georgy SR, Wilanowski T, et al:
Targeting of the tumor suppressor GRHL3 by a miR-21-dependent
proto-oncogenic network results in PTEN loss and tumorigenesis.
Cancer Cell. 20:635–648. 2011. View Article : Google Scholar : PubMed/NCBI
|
